CDK13 and medulloblastoma: Additionally, the involvement of CDK12/13 in MYC-driven oncogenesis has been demonstrated in medulloblastoma.428 Compared to tumors with low MYC expression, medulloblastomas with high MYC expression are more sensitive to CDK12/13 inhibition, which synergizes with DNA-damaging agents like cisplatin and olaparib.428 These results highlight the potential therapeutic advantages of targeting CDK13 in cancer therapy, especially in MYC-driven cancers.